A highly efficient messenger RNA (mRNA) vaccine technology capable of simultaneously inducing strong antibody and immune cell responses even at low doses has been developed.


mRNA vaccines became widely known during the COVID-19 pandemic. Their rapid development and excellent efficacy have positioned them as next-generation vaccines. However, one limitation has been that large quantities are required to achieve sufficient immune effects, and increasing the dose can lead to side effects such as fever and pain.


Medical staff are filling syringes with mRNA vaccines. Photo unrelated to the article. Photo by Hyunmin Kim kimhyun81@

Medical staff are filling syringes with mRNA vaccines. Photo unrelated to the article. Photo by Hyunmin Kim kimhyun81@

View original image

The Korea Research Institute of Bioscience and Biotechnology (KRIBB) announced on April 1 that Dr. Hyun-Joo Cha and her team at the Nucleic Acid Therapeutics Research Center have developed a design method for a "next-generation mRNA vaccine platform" that overcomes the conventional limitations of mRNA vaccines and enables a strong immune response even at low doses.


This platform is characterized by simultaneous improvements to both the lipid nanoparticles that effectively deliver the core mRNA of the vaccine into bodily cells and the genetic design structure that supports the smooth functioning of the mRNA.


The principle of mRNA vaccines is to deliver a blueprint for protein production into human cells, allowing the cells to directly produce antigen proteins and thereby boost immunity. However, mRNA is easily degraded in the body and cannot cross cell membranes on its own, so nanoparticle technology to safely encapsulate and transport it into cells is essential.


Taking this into consideration, the research team developed a new nanoparticle that can deliver mRNA more effectively. By comparing 96 candidate substances, they confirmed that a new substance named "H9T6" delivers mRNA into cells more efficiently than those previously used.


Notably, this nanoparticle was observed to help mRNA escape from small sac-like compartments (endosomes) inside the cell before being degraded, allowing it to reach the protein production site and thus promoting the generation of immune proteins.


The team also improved the mRNA blueprint itself. mRNA contains untranslated regions (UTRs) at both ends that determine how much and for how long a protein is produced. The researchers analyzed hundreds of thousands of candidates to find the most effective structure, successfully enhancing protein production capability.


As a result, the research team emphasized that applying this newly developed technology led to strong antibody and immune responses even at lower doses compared to conventional methods.


Most importantly, "safety tests (toxicity evaluations)" simulating multiple doses of the mRNA vaccine revealed no side effects and showed only temporary reactions followed by recovery, confirming the platform's safety.


This research is significant not only because it improved the performance of a single vaccine, but also because it proposed a new development strategy for designing mRNA vaccines more efficiently.


Based on these findings, the research team expects that the platform can be expanded and applied not only in responding to emerging infectious diseases in the future but also in various mRNA-based vaccine and therapeutic areas such as cancer vaccines.


Dr. Cha stated, "The strength of this research lies in optimizing both mRNA delivery technology and genetic design, thereby addressing the limitations of existing vaccines. Now that we have established a foundation for developing highly effective vaccines at low doses, we anticipate broad application in responses to various infectious diseases and the development of next-generation vaccines in the future."



This research was supported by the Convergence Research Team Project of the National Research Council of Science & Technology (NST), the Ministry of Science and ICT's Nano and Material Technology Development Program, and major projects at KRIBB. The results were published in the international journal 'ACS Nano' on March 3.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing